UnknownPHASE2, PHASE3NCT06155955
Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A
Studying Hemophilia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chulalongkorn University
- Principal Investigator
- NUCHANUN KESSAKORNKing Chulalongkorn Memorial Hospital
- Intervention
- "Emicizumab", "HEMLIBRA®"(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 3-30 years · MALE
- Timeline
- 2023 – 2024
Study locations (1)
- King Chulalongkorn Memorial hospital, Bangkok, Thailand
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06155955 on ClinicalTrials.govOther trials for Hemophilia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07416604A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia AHoffmann-La Roche
- RECRUITINGPHASE3NCT07545395Safety of KN057 Prophylaxis in Patients With Haemophilia A or BSuzhou Alphamab Co., Ltd.
- RECRUITINGPHASE3NCT04563520SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisEmory University
- RECRUITINGPHASE4NCT07406139PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT06992076Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience RegistryInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT07101926Monitoring of Anti-TFPI in HemophiliaHospices Civils de Lyon
- RECRUITINGPHASE4NCT06941870Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophySanofi
- RECRUITINGNCT07314983Long-term Anticoagulation in a Patient With Severe Hemophilia AUniversity Hospital, Strasbourg, France